Related Experiment Video

Updated: Jun 24, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

Massimo Breccia1, Giuliana Alimena

  • 1Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it

Leukemia Research
|March 25, 2009
PubMed

Insights

Imatinib mesylate effectively treats certain cancers by inhibiting tyrosine kinases (TKs). This review details imatinib

Area of Science:

  • Oncology
  • Pharmacology
  • Metabolism

Background:

  • Imatinib mesylate is a targeted therapy inhibiting tyrosine kinases (TKs) crucial in cancer pathogenesis.
  • It is effective against chronic myeloid leukemia (CML), myeloproliferative disorders, dermatofibrosarcoma protuberans, and gastrointestinal tumors.
  • While generally well-tolerated, imatinib's impact on metabolism requires further investigation, particularly in CML patients.

Purpose of the Study:

  • To review the metabolic alterations induced by imatinib therapy.
  • Specifically focusing on changes in glucose, lipid, and bone metabolism.

Main Methods:

  • Literature review of studies reporting metabolic effects of imatinib.
  • Analysis of data on glucose, lipid, and bone metabolism in patients undergoing imatinib treatment.

Main Results:

  • Imatinib's inhibition of TKs like BCR/ABL, PDGF-R, and c-KIT is central to its therapeutic action.
  • Reported metabolic effects include alterations in glucose, lipid, and bone metabolism.
  • These changes can occur despite overall good drug tolerance.

Conclusions:

  • Imatinib therapy, while effective, can induce significant metabolic changes.
  • Understanding these effects on glucose, lipid, and bone metabolism is crucial for patient management.
  • Further research is needed to fully elucidate and manage imatinib-induced metabolic disturbances.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...